Up to 50% OFF. Every Online Course. Limited Time.

Learn More
Canadian Board of Aesthetic Medicine

Sclerotherapy Training: A Comprehensive Guide for Healthcare Professionals

Sclerotherapy training combines lower-limb venous anatomy, patient assessment, vein classification, treatment selection, sclerosant science, contraindications, complication awareness and aftercare to help healthcare professionals build a safety-focused foundation for treating appropriate superficial veins.

Venous Anatomy Spider Veins Reticular Veins Patient Assessment Sclerosants Clinical Safety
01 Lower-limb venous anatomy and classification
02 Patient assessment and treatment suitability
03 Sclerosant science and treatment principles
04 Complication prevention and aftercare

Sclerotherapy is an established treatment approach for selected superficial venous conditions, including certain telangiectasias, reticular veins and varicose veins.

Although the procedure may appear straightforward, responsible sclerotherapy practice requires considerably more than learning how to inject a visible vein.

The appearance of a vein does not, by itself, explain the underlying venous anatomy, hemodynamics or whether sclerotherapy is the appropriate treatment.

Healthcare professionals therefore need a foundation in lower-limb venous anatomy, vein classification, patient history, physical examination, contraindications, treatment alternatives, sclerosant principles, complication recognition and post-treatment care.

This guide from the Canadian Board of Aesthetic Medicine (CBAM) explores the clinical foundations healthcare professionals should understand when studying sclerotherapy.

Clinical Foundation

What Is Sclerotherapy?

Sclerotherapy involves introducing a sclerosing agent into an appropriate vein with the objective of producing a controlled response that ultimately leads to closure of the treated vessel.

It is commonly associated with the treatment of visible superficial leg veins, but the term encompasses different clinical scenarios and techniques.

Depending on the patient's venous condition and the practitioner's scope, sclerotherapy may be considered in the management of:

  • telangiectasias or spider veins;
  • reticular veins;
  • selected varicose veins;
  • selected superficial venous disease;
  • other appropriately assessed venous presentations.
Sclerotherapy is not simply a cosmetic injection. Visible leg veins may be part of a broader pattern of venous disease. Appropriate assessment should determine what is being treated and whether another diagnostic or therapeutic pathway is more appropriate.
SUPERFICIAL VEIN PRESENTATIONS TELANGIECTASIAS RETICULAR VEINS VARICOSE VEINS
Different venous presentations may require different assessment, diagnostic and treatment strategies.

Venous Anatomy

Why Lower-Limb Venous Anatomy Matters

A visible surface vessel is only one component of the lower-limb venous system.

SUP

Superficial Veins

Superficial venous anatomy includes networks that may contribute to visible telangiectatic, reticular and varicose presentations.

DEEP

Deep Venous System

The deep venous system has major implications for circulation, thrombotic risk and the evaluation of venous disease.

PERF

Perforating Veins

Perforating veins connect superficial and deep systems and contribute to the hemodynamics of lower-limb venous circulation.

VAL

Venous Valves

Venous valves help direct blood flow and are important when understanding reflux and chronic venous disease.

FLOW

Venous Reflux

Visible veins can sometimes coexist with underlying reflux, which may alter diagnostic and treatment considerations.

US

Duplex Ultrasound

Duplex assessment plays an important role in selected patients when underlying venous pathology needs further evaluation.

Visible does not necessarily mean isolated. A practitioner should understand when a superficial cosmetic presentation can be assessed clinically and when findings suggest the need for further venous evaluation or referral.

Classification

Spider Veins, Reticular Veins and Varicose Veins Are Not the Same

Telangiectasias & Reticular Veins

Telangiectasias are small visible superficial vessels commonly described as spider veins. Reticular veins are generally larger subdermal veins that may appear blue or green beneath the skin.

Their clinical assessment should consider distribution, symptoms, feeding vessels, previous treatment and whether there are signs of broader venous disease.

Varicose Veins & Venous Disease

Varicose veins represent larger dilated superficial veins and may be associated with venous reflux or chronic venous disease.

Symptoms such as heaviness, aching, edema, skin changes, ulceration or recurrent thrombophlebitis can change the clinical significance of a patient's presentation.

Before Treatment

Patient Assessment Comes Before Sclerotherapy

Appropriate patient selection is one of the most important components of sclerotherapy safety.

1

Clarify the Patient's Concern

Determine whether the concern is primarily cosmetic, symptomatic or associated with broader signs of venous disease.

2

Take a Relevant Medical History

Review previous venous disease, thrombosis, procedures, medications, allergies, pregnancy status, mobility and other clinically relevant risk factors.

3

Perform a Lower-Limb Examination

Assess the visible vein pattern and look for findings such as edema, skin changes, inflammation, ulceration or other features that may alter the treatment pathway.

4

Consider Underlying Venous Disease

Not every visible vein should automatically proceed to cosmetic treatment. Selected findings may warrant additional vascular assessment or duplex ultrasound.

5

Determine Treatment Suitability

The practitioner should evaluate indications, contraindications, treatment alternatives, expected outcomes and the patient's individual risk-benefit profile.

Professional Education

What Should Comprehensive Sclerotherapy Training Cover?

Venous Anatomy Superficial, deep and perforating systems, venous valves and clinically relevant circulation.
Vein Classification Telangiectasias, reticular veins, varicose veins and broader chronic venous presentations.
History & Examination Patient symptoms, medical history, risk factors and physical assessment.
Treatment Selection Understanding when sclerotherapy may be appropriate and when another treatment or referral should be considered.
Sclerosant Science Major sclerosant categories, mechanisms, product-specific considerations and limitations.
Contraindications Identifying patients or clinical circumstances where treatment may be inappropriate or require caution.
Complications Expected reactions, adverse events, serious complications and early recognition.
Aftercare Patient education, follow-up, compression concepts and post-treatment expectations.
Clinical Judgment Integrating anatomy, diagnosis, patient factors, treatment goals and safety into decision-making.

Treatment Science

Understanding Sclerosing Agents

Sclerosing agents are substances used to produce a controlled effect on the treated vein.

Different agents have different pharmacological properties, approved indications, concentrations, formulations, safety profiles and regulatory status.

Sclerotherapy education should therefore help practitioners understand:

  • major categories of sclerosants;
  • basic mechanisms of action;
  • product-specific labeling;
  • differences between formulations;
  • patient and vessel considerations;
  • potential adverse reactions;
  • regulatory differences between jurisdictions.
A sclerosant is not simply an interchangeable injection solution. Product selection and use should follow current product labeling, clinical evidence, local regulation and practitioner scope. Training material should not substitute for product-specific prescribing information.
TREATMENT CONCEPT VISIBLE VEIN VESSEL RESPONSE Controlled vessel treatment requires appropriate patient, product and clinical selection.

Treatment Concepts

Liquid and Foam Sclerotherapy Are Related but Not Identical

Liquid Sclerotherapy

Liquid sclerosant is used in selected venous presentations, with the appropriate product and treatment approach depending on the vessel, patient and regulatory context.

Practitioners should understand product characteristics, indications and limitations rather than assuming all liquid sclerotherapy is performed in the same way.

Foam Sclerotherapy

Foam formulations alter the physical characteristics and interaction of the sclerosant with blood and the vessel wall.

Foam also introduces distinct clinical and safety considerations. It should therefore be studied as a specific treatment concept, not merely as another form of the same injection.

Formulation matters. Evidence, adverse-event profiles and appropriate use can differ between sclerosants and between liquid and foam approaches. Clinical decisions should be product- and indication-specific.

Patient Selection

Contraindications and Situations Requiring Caution

One of the most valuable sclerotherapy skills is recognizing when not to proceed.

  • relevant thrombotic history or active thrombosis
  • known hypersensitivity to the intended sclerosant
  • pregnancy-related considerations
  • significant arterial disease
  • limited mobility or thrombotic risk factors
  • active local infection or inflammation
  • selected systemic medical conditions
  • complex or unexplained venous presentations
  • symptoms suggesting broader venous disease
  • circumstances requiring specialist assessment
Contraindications are not a one-line checklist. Absolute and relative contraindications can depend on the specific sclerosant, treatment type, patient's health, venous pathology and current professional guidance. Product labeling and contemporary guidelines should always be consulted.

Risk Management

Potential Side Effects and Complications of Sclerotherapy

Sclerotherapy is generally well established, but both local and systemic adverse events have been reported. Training should distinguish expected post-treatment changes from complications requiring evaluation.

Hyperpigmentation Post-treatment pigmentation can occur along the course of a treated vessel and may persist for variable periods.
Telangiectatic Matting Networks of fine new vessels can appear in or around a treated region after sclerotherapy.
Superficial Thrombosis Localized thrombotic or inflammatory changes may occur within treated superficial veins.
Skin Injury Tissue injury, ulceration or necrosis are uncommon but clinically significant complications.
Thromboembolic Events Deep venous thrombosis and pulmonary embolic events are among the serious complications described in the literature.
Allergic Reactions Hypersensitivity and, rarely, serious systemic reactions can occur with sclerosing agents.
Neurological Symptoms Visual and neurological adverse events have been reported, particularly in association with some foam treatments.
Nerve Injury Nerve-related complications are uncommon but have been described following sclerotherapy.
Unexpected Pain or Swelling Symptoms outside the expected recovery pattern may require further clinical evaluation.

Common Aesthetic Concerns

Hyperpigmentation and Telangiectatic Matting After Sclerotherapy

Not all sclerotherapy adverse effects are medical emergencies. Some of the more frequently discussed post-treatment concerns are aesthetic, including pigmentation and telangiectatic matting.

Post-sclerotherapy hyperpigmentation can appear along the course of a treated vessel. Reported frequency varies considerably between studies and appears to depend on factors including the treated veins, sclerosant, formulation and concentration.

Telangiectatic matting refers to the development of fine new superficial vessels around a treated area.

These outcomes are important because patient satisfaction depends not only on vein clearance but also on realistic expectations about recovery, temporary appearance changes and possible persistent cosmetic effects.

Outcome counseling is part of treatment safety. Patients should understand that cosmetic improvement may take time and that pigmentation, matting or residual vessels can occur even when the treatment is otherwise clinically successful.

Aftercare

Compression, Follow-Up and Patient Instructions

Post-treatment care is an important component of the sclerotherapy pathway.

Depending on the clinical scenario, sclerosant, vein type, professional guidance and treating clinician's protocol, aftercare may include considerations related to:

  • compression;
  • mobility;
  • expected local reactions;
  • activity guidance;
  • skin care;
  • warning symptoms;
  • follow-up assessment;
  • future treatment planning.

Training should help practitioners communicate clearly what patients may reasonably expect after treatment and which symptoms require clinical reassessment.

Treatment Selection

Sclerotherapy Is One Option Within Vein Treatment

A key component of professional education is understanding that not every visible or symptomatic vein should receive the same treatment.

SCL

Sclerotherapy

Can be appropriate for selected superficial venous presentations after appropriate patient and vein assessment.

LAS

Transcutaneous Laser

Laser-based treatment may be considered for selected superficial vessels depending on vessel characteristics and patient factors.

VEN

Venous Intervention

Larger varicose veins or underlying reflux may require different endovenous, surgical or specialist treatment strategies.

The best treatment is diagnosis-dependent. Training should teach clinicians to evaluate whether sclerotherapy fits the patient's venous presentation rather than treating every visible vessel with the same modality.

Learning Pathway

Can Sclerotherapy Training Be Completed Online?

Online Training Can Build Clinical Knowledge

  • venous anatomy;
  • vein classification;
  • patient history;
  • physical examination concepts;
  • treatment indications;
  • contraindications;
  • sclerosant science;
  • equipment principles;
  • complication awareness;
  • patient instructions;
  • compression concepts;
  • case-based decision-making.

Hands-On Training Develops Procedural Skill

Sclerotherapy requires practical skills involving patient positioning, vessel assessment, equipment handling, injection control and real-time clinical decision-making.

These psychomotor competencies cannot be established solely through online lessons.

For eligible healthcare professionals, supervised practical training can therefore complement the theoretical and clinical foundation developed online.

Online education and procedural competency are different outcomes. Online training can prepare a practitioner with anatomy, assessment and safety knowledge. It does not independently establish competence to perform sclerotherapy on patients.

Professional Responsibility

Scope of Practice and Regulatory Considerations

The legal authority to assess venous disease, prescribe or obtain sclerosants, perform injections or independently provide sclerotherapy varies by jurisdiction and professional designation.

Requirements may depend on:

  • professional licence;
  • prescribing authority;
  • medication regulations;
  • delegation and supervision;
  • clinical facility requirements;
  • diagnostic responsibilities;
  • professional insurance;
  • training and demonstrated competency;
  • local vascular or aesthetic medicine regulations.
A course certificate does not expand professional scope. A Certificate of Completion documents education. It does not independently authorize a healthcare professional to prescribe a sclerosant, diagnose venous disease or perform sclerotherapy outside the limits of their licence and jurisdiction.

Evaluating Education

Questions to Ask Before Choosing Sclerotherapy Training

  1. Does the course teach lower-limb venous anatomy?
  2. Does it distinguish spider, reticular and varicose veins?
  3. Is patient history and physical examination included?
  4. Does it discuss signs of underlying venous disease?
  5. Does it explain when additional vascular assessment may be needed?
  6. Are treatment indications and alternatives covered?
  7. Does it teach sclerosant science rather than one-size-fits-all protocols?
  8. Are contraindications addressed in detail?
  9. Does it distinguish common side effects from serious complications?
  10. Are pigmentation and telangiectatic matting discussed?
  11. Does it cover thrombotic and vascular risks?
  12. Are patient instructions and aftercare included?
  13. Does it discuss compression concepts?
  14. Does it include case-based clinical reasoning?
  15. Does it distinguish online learning from practical competency?
  16. Does it explain scope-of-practice limitations?
Sclerotherapy Education at CBAM

Build Your Sclerotherapy Knowledge Foundation With CBAM

The CBAM Sclerotherapy Online Training is designed for healthcare professionals seeking a structured introduction to the clinical foundations of sclerotherapy.

The current program includes 13 structured lessons covering topics from varicose vein classification, patient history and physical examination to contraindications, complications, sclerosing solutions, equipment, treatment considerations, patient instructions and compression stockings.

The course contains approximately 1 hour and 47 minutes of structured lesson content and is designed for beginner and intermediate learners. Related webinars are also included.

After completing the lessons and passing the online assessment, eligible participants receive a CBAM Certificate of Completion.

Because sclerotherapy is a procedural medical treatment, CBAM distinguishes online clinical education from hands-on procedural competency. Practitioners should follow their professional scope, local regulations and appropriate practical training requirements before treating patients.

Explore Sclerotherapy Online Training

Key Takeaway

Sclerotherapy Training: The Bottom Line

Sclerotherapy should not begin with choosing a syringe or a sclerosing solution. It begins with understanding the patient's venous presentation.

A healthcare professional needs to distinguish a relatively simple superficial cosmetic concern from findings that may represent broader chronic venous disease.

That requires knowledge of venous anatomy, vein classification, history taking, physical examination, contraindications, treatment alternatives and the limitations of the procedure.

Training should also make clear that sclerotherapy is not risk-free. Hyperpigmentation and telangiectatic matting are recognized outcomes, while less common but more significant complications can include tissue injury, thrombotic events, allergic reactions and other systemic adverse events.

The goal of comprehensive education is therefore not simply to teach how sclerotherapy is performed.

It is to develop a clinical framework for deciding who should be treated, what should be treated, when sclerotherapy is appropriate, when further investigation is needed and when treatment should not proceed.

Frequently Asked Questions

Common Questions About Sclerotherapy Training

What is sclerotherapy?

Sclerotherapy is a treatment in which a sclerosing agent is introduced into an appropriate vein to produce a controlled response leading to closure of the treated vessel.

What conditions can sclerotherapy be used to treat?

Sclerotherapy is commonly used for selected telangiectasias, reticular veins and other appropriate superficial venous conditions. Suitability depends on the specific presentation, patient assessment and underlying venous pathology.

Are spider veins and varicose veins the same?

No. Spider veins are small superficial telangiectatic vessels, while varicose veins are larger dilated veins and may be associated with underlying venous reflux or chronic venous disease.

Why is venous anatomy important for sclerotherapy?

Understanding superficial, deep and perforating venous anatomy helps practitioners interpret visible veins within the wider lower-limb venous system and recognize when further assessment may be required.

What should sclerotherapy training include?

Comprehensive education should cover venous anatomy, vein classification, patient assessment, contraindications, treatment alternatives, sclerosant science, complications, aftercare and professional scope.

What are common side effects of sclerotherapy?

Local effects can include bruising, pigmentation, telangiectatic matting and inflammatory or thrombotic changes in treated superficial veins. The specific risk profile varies with the treatment and patient.

Can sclerotherapy cause hyperpigmentation?

Yes. Post-sclerotherapy hyperpigmentation is a recognized local adverse effect. Reported rates vary considerably between studies and treatment approaches.

What is telangiectatic matting?

Telangiectatic matting describes the appearance of networks of fine superficial blood vessels in or around a previously treated region.

What is the difference between liquid and foam sclerotherapy?

Liquid and foam approaches differ in formulation and physical behavior. These differences can influence clinical applications, treatment characteristics and adverse-event considerations.

Can sclerotherapy training be completed online?

Core knowledge such as venous anatomy, patient assessment, sclerosant science, contraindications and complications can be studied online. Practical procedural competency requires appropriate supervised hands-on experience.

Who can take CBAM's Sclerotherapy Online Training?

CBAM's current course is designed for physicians, nurse practitioners, registered nurses, dentists and international medical doctors and nurses. Clinical practice eligibility remains subject to local regulation and professional scope.

How many lessons are included in CBAM's sclerotherapy course?

The current CBAM program includes 13 structured lessons covering anatomy and classification, patient assessment, contraindications, complications, sclerosants, equipment, patient instructions and compression-related education.

Does a sclerotherapy certificate authorize me to perform the procedure?

No. A Certificate of Completion documents education but does not independently determine legal authority, prescribing rights or professional scope. Practitioners must comply with the rules of their profession and jurisdiction.

Evidence & Clinical Guidance

Sclerotherapy Evidence and Further Reading

Clinical evidence should be interpreted according to the specific venous condition, sclerosant, formulation, patient population and treatment setting. Results from one form of sclerotherapy should not automatically be generalized to another.

  1. Gloviczki P, Lawrence PF, Wasan SM, et al. The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society Clinical Practice Guidelines for the Management of Varicose Veins of the Lower Extremities: Part II. Journal of Vascular Surgery: Venous and Lymphatic Disorders.
  2. De Maeseneer MG, Kakkos SK, Aherne T, et al. European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. European Journal of Vascular and Endovascular Surgery.
  3. International Union of Phlebology. Sclerotherapy of Lower Limb Veins: Indications, Contraindications and Treatment Strategies to Prevent Complications — A Consensus Document. 2023.
  4. Nakano LCU, et al. Safety Concerns for Sclerotherapy of Telangiectases, Reticular and Varicose Veins. Pharmacology. 2016.
  5. Bossart S, et al. Skin Hyperpigmentation After Sclerotherapy With Polidocanol: A Systematic Review. Journal of the European Academy of Dermatology and Venereology.
  6. Cochrane Vascular. Treatment for Telangiectasias and Reticular Veins. Systematic review evaluating sclerotherapy and other treatment options.
  7. Current product-specific regulatory labeling and local professional guidance should be reviewed before the use of any sclerosing agent.
Professional education notice: This guide is intended for healthcare professional education and general informational purposes only. It does not provide patient-specific medical advice, diagnostic recommendations, sclerosant selection instructions, drug concentrations, dosage, injection volumes, injection technique, foam preparation instructions or individualized treatment protocols. Sclerosing agents differ in approved indications, formulations, labeling, contraindications and regulatory status. Healthcare professionals should use current product labeling, peer-reviewed evidence, vascular or phlebology guidance, appropriate hands-on education and local scope-of-practice rules. Patients with symptoms or findings suggestive of significant venous disease may require additional vascular evaluation. Serious complications following sclerotherapy may require urgent or emergency medical assessment. Completion of an online educational program does not independently authorize a healthcare professional to prescribe, purchase, prepare or administer a sclerosing agent or to practise outside their professional scope.